A Phase II, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2010
At a glance
- Drugs Abatacept (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 08 Jun 2009 New trial record.